#1 Clinical Trials Search in Europe

Cariprazine

This article examines the use of cariprazine, an atypical antipsychotic medication, in various clinical trials. Cariprazine has shown potential in treating conditions such as bipolar disorder, schizophrenia, social anxiety disorder, and attention-deficit/hyperactivity disorder (ADHD). The trials aim to evaluate the drug’s efficacy, safety, and tolerability across different patient populations and dosage regimens.

Table of Contents

What is Cariprazine?

Cariprazine, also known by its brand name Vraylar, is a medication used to treat various mental health conditions[1]. It belongs to a class of drugs called atypical antipsychotics, which work differently from older antipsychotic medications[1]. Cariprazine is approved by the U.S. Food and Drug Administration (FDA) for use in adults, but research is ongoing to explore its potential benefits in other age groups and conditions[2].

Conditions Treated with Cariprazine

Cariprazine is used to treat several mental health conditions, including:

  • Schizophrenia: A severe mental disorder characterized by disturbances in thinking, perception, and behavior[3].
  • Bipolar I Disorder: A mood disorder that causes episodes of depression and mania (extreme highs)[4].
  • Bipolar Depression: The depressive phase of bipolar disorder[1].

Additionally, research is being conducted to explore the potential use of cariprazine in treating other conditions such as:

  • Social Anxiety Disorder: A condition characterized by intense fear and avoidance of social situations[5].
  • Attention-Deficit/Hyperactivity Disorder (ADHD): A neurodevelopmental disorder that affects attention, hyperactivity, and impulsivity[6].
  • Autism Spectrum Disorder (ASD): A developmental disorder that affects communication and behavior[2].

How Cariprazine Works

Cariprazine works by affecting certain chemicals in the brain, primarily dopamine and serotonin. It is a partial agonist at dopamine D3 and D2 receptors, which means it can both activate and block these receptors depending on the situation[1]. This unique mechanism of action is thought to help regulate mood and behavior in various mental health conditions.

Specifically, cariprazine has a higher affinity for D3 receptors, which are found in areas of the brain involved in mood and cognition. This characteristic may contribute to its effectiveness in treating both the positive symptoms (such as hallucinations and delusions) and negative symptoms (such as lack of motivation and social withdrawal) of schizophrenia[3].

Dosage and Administration

Cariprazine is typically taken orally in the form of capsules or oral solution. The dosage can vary depending on the condition being treated and the individual patient’s response. Some general guidelines include:

  • For adults with schizophrenia or bipolar disorder: Doses typically range from 1.5 mg to 6 mg per day[4].
  • For pediatric patients (ages 10-17) with bipolar depression: Doses may range from 1.5 mg to 3 mg per day, adjusted based on age and weight[7].

It’s important to note that dosage should always be determined by a healthcare professional and may be adjusted over time based on the patient’s response and any side effects experienced.

Efficacy of Cariprazine

Clinical trials have shown cariprazine to be effective in treating various mental health conditions:

  • In schizophrenia, cariprazine has demonstrated improvements in symptoms as measured by the Positive and Negative Syndrome Scale (PANSS)[3].
  • For bipolar depression, studies have shown significant improvements in depressive symptoms using scales such as the Montgomery-Asberg Depression Rating Scale (MADRS)[4].
  • Research is ongoing to evaluate its effectiveness in other conditions like social anxiety disorder and ADHD[5][6].

Potential Side Effects

Like all medications, cariprazine can cause side effects. Common side effects may include:

  • Akathisia (a feeling of inner restlessness)
  • Insomnia (difficulty sleeping)
  • Headache
  • Weight gain
  • Nausea

More serious side effects, though less common, can include changes in metabolism, increased blood sugar, and movement disorders. It’s important to discuss any side effects with your healthcare provider[3].

Ongoing Research

Several clinical trials are currently underway to further explore the potential uses and effects of cariprazine:

  • Studies in pediatric populations with autism spectrum disorder to evaluate safety and effectiveness[2].
  • Research on its potential use in treating social anxiety disorder[5].
  • Investigations into its efficacy as an adjunct treatment for ADHD[6].

These ongoing studies aim to expand our understanding of cariprazine and potentially broaden its therapeutic applications in the future.

Aspect Details
Drug Name Cariprazine (also known as Vraylar)
Drug Class Atypical antipsychotic
Mechanism of Action Partial agonist at dopamine D3 and D2 receptors, with affinity for serotonin receptors
Conditions Studied Bipolar disorder, Schizophrenia, Social Anxiety Disorder, ADHD
Administration Oral capsules or solution, daily dosing
Dosage Range 0.5 mg to 12 mg per day, depending on the condition and study
Trial Durations 6 to 48 weeks or longer
Primary Outcome Measures Changes in symptom severity scales (e.g., MADRS, PANSS, YMRS)
Safety Assessments Adverse events, laboratory values, vital signs, ECG
Special Populations Adults, pediatric patients with autism spectrum disorder

FAQ

  • What is cariprazine and how does it work? Cariprazine is an atypical antipsychotic medication that acts as a partial agonist at dopamine D3 and D2 receptors. It also has affinity for various serotonin receptors. This unique mechanism of action is thought to help regulate neurotransmitter activity in the brain, potentially improving symptoms of various mental health disorders.
  • What conditions is cariprazine being studied for in clinical trials? Clinical trials are investigating cariprazine for several mental health conditions, including bipolar disorder, schizophrenia, social anxiety disorder, and as an adjunct treatment for attention-deficit/hyperactivity disorder (ADHD).
  • How is cariprazine administered in these trials? Cariprazine is typically administered orally in the form of capsules or oral solution. The dosage varies depending on the specific trial and condition being studied, ranging from 0.5 mg to 12 mg per day.
  • What are some common outcome measures used in cariprazine trials? Common outcome measures include changes in symptom severity scales such as the Montgomery-Asberg Depression Rating Scale (MADRS) for depression, the Positive and Negative Syndrome Scale (PANSS) for schizophrenia, and the Young Mania Rating Scale (YMRS) for bipolar disorder. Safety and tolerability are also assessed through monitoring adverse events and changes in laboratory values.
  • How long do these clinical trials typically last? The duration of cariprazine clinical trials varies widely, ranging from 6 weeks to 48 weeks or longer. Some studies include an initial treatment phase followed by an extension period to assess long-term effects and safety.

Ongoing Clinical Trials on Cariprazine

  • Study Comparing Lithium and Cariprazine for Treating Bipolar Depression in Patients with Bipolar Type 1 or 2 During a Depressive Episode

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on the Effect of Clozapine and Drug Combination for Patients with Schizophrenia Experiencing First-Line Treatment Failure

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany Italy Spain

  • Study on the Effects of Cariprazine on Cognitive Function in Schizophrenia Patients Needing Antipsychotic Treatment Adjustment

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria

  • Study on the Effectiveness and Safety of Cariprazine for Adolescents (13-17 years) with Schizophrenia

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Romania

  • Study on the Safety and Tolerability of Cariprazine for Treating Schizophrenia in Adolescents Aged 13-17

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Germany Romania

Glossary

  • Atypical antipsychotic: A newer class of antipsychotic medications that generally have fewer side effects than older, typical antipsychotics. They are used to treat various mental health conditions, including schizophrenia and bipolar disorder.
  • Bipolar disorder: A mental health condition characterized by extreme mood swings that include emotional highs (mania or hypomania) and lows (depression).
  • Schizophrenia: A chronic and severe mental disorder that affects how a person thinks, feels, and behaves. Symptoms can include hallucinations, delusions, and disorganized speech and behavior.
  • Social Anxiety Disorder (SAD): A mental health condition characterized by intense fear or anxiety in social situations, often leading to avoidance of social interactions.
  • Attention-Deficit/Hyperactivity Disorder (ADHD): A neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity that interferes with functioning or development.
  • Dopamine: A neurotransmitter in the brain that plays a role in reward, motivation, and movement. It is often implicated in various mental health disorders.
  • Serotonin: A neurotransmitter that helps regulate mood, anxiety, and happiness. It is a target for many antidepressant medications.
  • Partial agonist: A substance that binds to and activates a receptor but only produces a partial response compared to a full agonist.
  • Montgomery-Asberg Depression Rating Scale (MADRS): A clinician-administered scale used to assess the severity of depressive symptoms in patients with mood disorders.
  • Positive and Negative Syndrome Scale (PANSS): A medical scale used for measuring symptom severity of patients with schizophrenia, assessing both positive and negative symptoms.
  • Young Mania Rating Scale (YMRS): A rating scale used to evaluate manic symptoms in patients with bipolar disorder.
  • Clinical Global Impression (CGI) scale: A tool used by healthcare professionals to assess the overall severity of a patient's illness and improvement over time.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. https://clinicaltrials.gov/study/NCT05060549
  2. https://clinicaltrials.gov/study/NCT04382885
  3. https://clinicaltrials.gov/study/NCT05368558
  4. https://clinicaltrials.gov/study/NCT00852202
  5. https://clinicaltrials.gov/study/NCT05384483
  6. https://clinicaltrials.gov/study/NCT04843423
  7. https://clinicaltrials.gov/study/NCT04777357